Group sales and earnings

Fresenius continues to expect Group sales to grow organically with a compounded annual growth rate (CAGR) of 4% to 7% during 2020 to 2023. Group net income1,2 is projected to increase organically with a CAGR of 5% to 9% during 2020 to 2023. Fresenius expects its sales growth and efficiency improvement initiatives as well as Fresenius Kabi’s biosimilarsBiosimilarsA biosimilar is a drug that is “similar” to another biologic drug already approved. business to drive an acceleration of Group earnings growth over that period. Small and medium-sized acquisitions are expected to contribute an incremental CAGR of approx. 1%-point to both sales and net income growth.

1 Net income attributable to shareholders of Fresenius SE & Co. KGaA
2 Before special item

Download (XLSX, 35 KB)
Group financial medium-term targets
CAGR 2020 – 2023
Organic sales growth 4% to 7%
Organic net income growth1, 2 5% to 9%
1 Before special items
2 Net income attributable to shareholders of Fresenius SE & Co. KGaA

COVID-19 will continue to impact Fresenius’ operations in 2021. Current burdens and constraints caused by COVID-19 are expected to recede only in H2/21. The expected improvement in the Group’s relevant business environment from H2/21 is heavily dependent on continuously increasing levels of vaccination coverage. These assumptions are subject to considerable uncertainty.

Fresenius closely monitors the development of COVID-19 case numbers, and the associated various containment measures being enacted in many of the Company’s relevant markets. The Group’s FY/21 guidance does not reflect any potential further containment measures that could have a significant and direct impact on the health care sector without any appropriate compensation.

Download (XLSX, 36 KB)
Group financial targets 2021
Targets 20211 Fiscal year 20202
Sales growth (in constant currency) Low-to-mid single-digit percentage growth € 36,277 m
Net income3 growth (in constant currency) At least broadly stable € 1,796 m
Dividend Further increase intended Proposal +5% per share
1 Including expected COVID-19 effects, before special items
2 Before special items, including COVID-19 effects 
3 Net income attributable to shareholders of Fresenius SE & Co. KGaA

Health care sector and markets

Sales and earnings by business segment